<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824157</url>
  </required_header>
  <id_info>
    <org_study_id>5826-18-SMC</org_study_id>
    <nct_id>NCT04824157</nct_id>
  </id_info>
  <brief_title>Ketamine IV Classic Protocol : Five Years Follow up</brief_title>
  <official_title>Ketamine IV Classic Protocol : Five Years Follow up Clinical Evaluation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who suffer from MDD recieved ketamnie (2014-15) in open study will be addressed and&#xD;
      there depression mood will be evaluated using the rating scale that were used in the original&#xD;
      research. In addition time of relapse and questions about their medications and drug use will&#xD;
      be performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who suffer from Major Depressive disorder and are outpatients in our clinic and,&#xD;
      received in the years (2014-15) ketamine in open study will be addressed and there depression&#xD;
      mood will be evaluated using the rating scale that were used in the original research. In&#xD;
      addition time of relapse and questions about their medications and drug use will be&#xD;
      performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2019</start_date>
  <completion_date type="Actual">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mood that will be evaluated using the MADRAS Montgomery-Asberg Depression Rating Scale&quot;.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Drug Abuse</condition>
  <condition>Medications</condition>
  <condition>Relapse</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non</intervention_name>
    <description>Follow up</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who participated in ketamine study 1126 and are willing to participate&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who participated in ketamine study 1126&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel HaShomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Revital Amiaz</investigator_full_name>
    <investigator_title>Head of Department Psychiatry B</investigator_title>
  </responsible_party>
  <keyword>Major depressive disorder</keyword>
  <keyword>ketamine</keyword>
  <keyword>follow up</keyword>
  <keyword>Antidepressants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to share data with other resarchers that will be interested.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Up to 6 weeks from demand</ipd_time_frame>
    <ipd_access_criteria>Six weeks</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

